Reason: Acquired by Medtronic
Last recorded trade on: April 29, 2022
Source: https://news.medtronic.com/2022-05-13-Medtronic-completes-acquisition-of-Intersect-ENT
P/E ratio for Intersect ENT (XENT)
P/E ratio at the end of 2020: -10.2
According to Intersect ENT's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -12.7207. At the end of 2020 the company had a P/E ratio of -10.2.
P/E ratio history for Intersect ENT from 2014 to 2020
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2020 | -10.2 | -43.72% |
| 2019 | -18.2 | -48.21% |
| 2018 | -35.1 | -39.35% |
| 2017 | -57.9 | 325.56% |
| 2016 | -13.6 | -37.67% |
| 2015 | -21.8 | 83.49% |
| 2014 | -11.9 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 | -5.48 | -56.93% | 🇺🇸 USA |
 | -9.16 | -28.02% | 🇺🇸 USA |
 | 24.0 | -288.91% | 🇺🇸 USA |
 | 24.5 | -292.73% | 🇮🇪 Ireland |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.